The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ESLA | +320.11% | N/A | N/A | -75% |
| S&P | +19.89% | +109.18% | +15.89% | +54% |
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $34.72M | -9.1% |
| Net Income | -$5.54M | -40.3% |
| EBITDA | -$5.54M | -40.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.32M | -68.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -324.86% | 0.0% |
| Return On Invested Capital | -171.09% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.41M | -42.3% |
| Operating Free Cash Flow | -$0.41M | -42.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 9.94 | 56.60 | 236.48 | -18.96 | -519.87% |
| Price to Tangible Book Value | 9.94 | 56.60 | 236.57 | -18.96 | -519.89% |
| Price to Free Cash Flow TTM | 2.75 | 2.88 | - | ||
| Enterprise Value to EBITDA | -11.91 | -40.48 | -15.74 | -6.02 | -30.58% |
| Free Cash Flow Yield | 36.4% | 34.8% | - | ||
| Return on Equity | -314.6% | - | |||
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
